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INTRODUCTION
Nanoparticulate delivery systems, such as those based on poly(lactic-co-glycolic acid) (PLGA) polymers, have been studied extensively for many years. PLGA polymers have the advantage of being well characterized and already commercially used for microparticulate drug delivery systems. 1 PLGA polymers are biocompatible, biodegradable, and bioresorbable. 2 PLGA nanoparticles can be formed by interfacial deposition following solvent displacement technique. 3 Several compounds such as indomethacin 4 and muramyl dipeptide MDB-B30 5 have been incorporated in this technique.
The interfacial deposition following solvent displacement technique 3 differs from nanosphere preparation method by introduction of an oily component into the polymer-organic solution. First, the polymer, phospholipid mixture, and benzyl benzoate are dissolved in acetone. Then, the organic solution is poured into an aqueous phase containing a surfactant (eg, poloxamer) under moderate stirring. Acetone diffuses immediately into the aqueous phase, inducing the deposition and precipitation of the polymer around the oily droplets. 6 Itraconazole is weakly basic (pKa = 3.7) and highly hydrophobic (octanol/water partition coefficient at pH = 8.1, log P = 5.66). 7 It is insoluble in water, so the first route of administration is oral. Large interindividual as well as intraindividual variations of its oral bioavailability have been reported. 8 The development of an injectable dosage form would be extremely useful to overcome this drawback and to offer a dosage form that would allow the necessary therapeutic dose to be achieved. This implies a preparation containing not less than 0.500 mg/mL of itraconazole. The application of an optimization technique consisting of statistical design to pharmaceutical formulation development would provide an efficient and economical method to acquire the necessary information to understand the relationship between controllable (independent) variables and performance or quality (dependent) variables or responses. 9 In addition, the optimization process provides a method to develop an empirical model equation to characterize the response as a function of the different independent variables.
The technique of optimization is well reported in the literature for the development of tablet formulations, [10] [11] [12] microcapsules, 13,14 fluid bed spray coating, 15 hydrocolloid dressing, 16 and suspension. 17 The purpose of this study was to investigate the utility of a 2 3 factorial design and optimization process to develop and improve formulation of PLGA nanoparticles containing itraconazole. The optimization process was used to generate a model equation that provides a means of evaluating changes in response due to changes in the independent variable levels.
MATERIALS AND METHODS

Materials
Poly(lactic-co-glycolic acid) with a monomer ratio of 50:50 was obtained from Boehringer Ingelheim (Ingelheim, Germany). Itraconazole was purchased from Tricon Enterprises (batch no. IT008090) (Mumbai, India). Benzyl benzoate was obtained from Sigma (St Louis, MO). Poloxamer F68 was purchased from BASF (Montreal, Canada). Acetone (high performance liquid chromatography [HPLC] grade) was obtained from Mallinckrodt Baker (Paris, France). Acetonitrile and methanol (both HPLC grade) were purchased from BDH (Dorset, Poole Dorset, UK).
Preparation of Nanoparticles
PLGA nanoparticles containing itraconazole (PGNI) were prepared according to the method already described. 3 Briefly, the accurate content of PLGA, benzyl benzoate, and itraconazole were dissolved in 10 mL acetone. The organic phase was added at a constant flow rate (0.3 mL/min) under mechanical stirring at 750 rpm to 25 mL of an aqueous phase containing 0.25% of nonionic surfactant (pluronic F68). The resulting mixture turned milky instantaneously because of the formation of nanoparticles by interfacial polymer deposition. Acetone was removed by evaporation under vacuum, and the final volume was adjusted to 10 mL.
Experimental Design
A 2 3 full factorial design with 2 replicates was used in this study. The 3 independent variables investigated were the concentrations of PLGA (X 1 ), benzyl benzoate (X 2 ), and itraconazole (X 3 ). The level of the 3 independent variables is shown in Table 1 , and the design is presented in Table 2 . Five replicates at the center of the design were investigated to allow for an independent estimation of the experimental error and to check the linearity of the factor effects. 18 The effect of the previously mentioned variables was investigated on the following responses: the particle size and the encapsulation efficiency.
Determination of Particle Size
The particle size of PGNI was determined by photon correlation spectroscopy (PCS) using an Autosizer IIC (Malvern 4700 laser spectrometer, Malvern Instruments, Malvern, UK) with a He-Ne laser. The signals were processed by Malvern 7032-N multibit correlator (Malvern Instruments). For particle size analysis, PGNI were dispersed in ultrapure water filtrated through a 0.22-µm nylon membrane for minimizing dust. Measurements were carried out at 30°C using a 632.8 nm laser at an angle of 90°.
Determination of Encapsulation Efficiency
The amount of itraconazole entrapped in the nanoparticles (ITRAe) was assayed by HPLC in the suspension after filtration through a sintered glass filter (porosity 4, mesh size 5-15 µm). This filtration step retains the unassociated itraconazole that precipitates in the aqueous phase just after preparation because of its insolubility. The method was modified from the method described by Law et al 19 using reverse phase (RP)-HPLC equipped with UV detector (263 nm). The chromatographic analysis was performed on Waters systems (Waters Corp, Milford, MA), using RP Lichrospher 60 RP-select B, 5 µm; 4.6 × 120 mm. After appropriate dilution of the sample in methanol, 0.5 mL of internal standard solution was added. The samples were eluted with acetonitrile:water:diethylamine (50:50:0.05), at a constant flow rate of 1.1 mL/min. Ketoconazole was used as an internal standard. The retention time of ketoconazole and itraconazole were 3.1 and 6 minutes, respectively. Encapsulation efficiency was expressed as the percentage of drug versus the amount of drug in organic phase.
Response Surface Analysis
Response surface methodology is a collection of mathematical and statistical techniques used for the modeling and analysis of problems in which a response of interest is influenced by several variables and the objective is to optimize this response. 
where Y is the measured response of the particle size (nm), the amount of itraconazole entrapped in the nanoparticles (µg/mL) (ITRAe), and encapsulation efficiency (ITRAe [%]), B 0 , intercept term, B i and B ij are, respectively, the measures of the effects of variables X i and X i X j . The variable X i X j represents the first order interactions between X i and X j (i < j).
Data were analyzed using analysis of variance (ANOVA), and regression coefficients were calculated.
The error mean square was calculated according to the following equation:
where Y i is the response of the ith replicates at the center of the design, Y is the mean, and n c is the number of the replicates.
The curvature sum of squares was calculated according to the following equation: where n f and n c are the number of the factorial experiments and the experiments at the center, respectively; f Y and c Y are the means of the corresponding observations. SS curvature with 1 degree of freedom was compared with the error mean square to check any curvature in the response surface as a function of different factors effect.
A relatively straightforward approach to optimizing several factor responses that works well when there are only a few process variables is to overlay the contour plots for each response. Another useful approach to optimization of multiple responses is to use the simultaneous optimization technique popularized by Derringer and Suich. 18 Their procedure makes use of desirability functions. The general approach is to first convert each response y i into an individual desirability function d i that varies over the range 0 ≤ d i ≤ 1, where if the response y i is at its goal or target, then d i = 1, and if the response is outside an acceptable region, d i = 0. Then, the design variables are chosen to maximize the overall desirability as follows:
where there are m responses.
18
RESULTS AND DISCUSSION
The effects of the different combinations of concentration of PLGA (X 1 ), benzyl benzoate (X 2 ), and itraconazole (X 3 ), illustrated in Table 2 , on the particle size (nm) and the amount of itraconazole entrapped in the nanoparticles (µg/mL) (ITRAe) of PGNI are shown in Table 3 as observed response.
Analysis of data was carried out using ANOVA, and the individual parameter was evaluated with the F test. Results of the response surface analysis are summarized in Table 4 . The application of response surface methodology 20 yielded the following regression equations, which suggest an empirical relationship between the values of responses and the independent variables in coded unit: Where Y 1 , Y 2 , and Y 3 are the responses: the particle size (nm), the amount of itraconazole entrapped in the nanoparticles (ITRAe) (µg/mL), and encapsulation efficiency (ITRAe [%]), respectively. X 1 , X 2 , and X 3 are the code values of the independent variables (PLGA, benzyl benzoate, and itraconazole).
The predicted values were calculated by using the mathematical model from Equations 9 and 10, tabulated in Table  3 .
On the particle size, the Fisher F test with a very low probability value (P model > F less than 0.0001) ( Table 4) demonstrated a very high significance for the regression model. 19 The goodness of fit of the model was checked by the adjusted determination coefficient ( adjusted R 2 ). The determination coefficient (R 2 ) is a measure of the amount of reduction in the variability of Y obtained by using the regressor variables X 1 , X 2 , and X 3 . However, a large value of R 2 does not necessarily imply that the regression model is a good one. Adding a variable to the model will always increase R 2 , regardless of whether the additional variable is significant or not. The adjusted R 2 statistic will not always increase as variables are added to the model. If unnecessary variables are added, the value of adjusted R 2 will often decrease. 18 The results show that the value of the determination coefficient (R 2 = 0.9992) was as high as the value of the adjusted determination coefficient (adjusted R 2 = 0.9989), which indicated a high significance of the model. 20 A higher value of the correlation coefficient (R = 0.9996) signified an excellent correlation between the independent variables. 21 At the same time, a relatively low value of the coefficient of variation (CV = 1.10) indicated improved precision and reliability of the conducted experiments. It is obvious that the concentration of PLGA, benzyl benzoate, and itraconazole had significant effect on the particle size of the nanoparticles. Figures 1A and 1B show the increasing effect of PLGA, itraconazole, and benzyl benzoate. A significant synergistic interaction between PLGA and itraconazole at P < .001 was observed. This interaction is reflected by the pattern of the lines of Figure 1B . A significant (P < .001) antagonistic interaction was observed between PLGA and benzyl benzoate. This interaction is reflected by the pattern of the lines of Figure 1A . The dot at the center of the contour plot defined as the design points was 5 center points. The linearity over the region of exploration was tested by the F curve. Although the F curvature for the response surface was significant at P < .001, the developed model equation was a good prediction of the particle size for the 4 formulas presented in Table 5 .
On the amount of itraconazole entrapped in the nanoparticles (ITRAe), the Fisher F test with a very low probability value (P model > F less than 0.0001) (Table 4 ) demonstrated a very high significance for the regression model. 20 The value of the determination coefficient (R 2 = 0.9999) was as high as the value of the adjusted determination coefficient (Adjusted R 2 = 0.9999), which indicated a high significance of the model. 20 A relatively low value of the coefficient of variation (CV = 0.80) indicated improved precision and reliability of the conducted experiments. 22 It is obvious that the concentration of PLGA, benzyl benzoate, and itraconazole also had significant effect on the amount of itraconazole entrapped in the nanoparticles (ITRAe). Figures 2A and 2B show the increasing effect of [PLGA], itraconazole, and benzyl benzoate, respectively. The increasing effect shown with benzyl benzoate (P < .001) was due to itraconazole solubility in benzyl benzoate. The greater the concentration of benzyl benzoate in organic phase, the higher becomes itraconazole dissolved in benzyl benzoate. A significant synergistic interaction between PLGA and itraconazole at P < .001 was observed. This interaction is reflected by the pattern of the lines of Figure 2A . A significant (P < .001) synergistic interaction also was observed between benzyl benzoate and itraconazole. This interaction is reflected by the pattern of the lines of Figure 2B . The linearity over the region of exploration was tested by the F curve. Although the F curvature for the response surface was significant at P < .001, the developed model equation was a good prediction of the amount of itraconazole entrapped in the nanoparticles for the 4 formulas presented in Table 5 . Figure 3A indicates that there are a number of combinations of concentration of PLGA, benzyl benzoate, and itraconazole that will result in a satisfactory process. Figure 3B Figure 3B shows that there is no boundary that must be met by the process.
Using the desirability approach, the target of ITRAe was chosen to be 500 µg/mL, while the lower limit was equal to 450 µg/mL, and the upper limit was 550 µg/mL. The particle was set equal at a minimum between 300 and 400 nm. Finally, the ITRAe (%) ranged from 60% to 70%. Four solutions were found. The solution having the highest overall desirability (D = 0.769) was composed of 10 mg/mL of PLGA, 16.94 µg/mL of benzyl benzoate, and 1001.01 µg/mL of itraconazole. The desirability function response surface and contour plot are shown in Figures 4A and 4B , respectively. Verification of the predicted value was made by using nanoparticles prepared using the optimized conditions (Formula 4 in Table 5 ). The particle size and amount of itraconazole entrapped in nanoparticles are in the 95% prediction interval. These results therefore corroborate the predicted values, and the effectiveness of the model.
CONCLUSION
PLGA nanoparticles containing itraconazole were successfully prepared by using solvent displacement technique. The formulation study using 2 3 factorial design and response surface methodology allowed one to obtain the optimum formulation. The concentration of PLGA, benzyl benzoate, and itraconazole had significant effect on the particle size of the nanoparticles , and the amount of itraconazole entrapped in the nanoparticles (ITRAe).The PLGA nanoparticles containing itraconazole prepared by 10 µg/mL of PLGA, 16 .94 µg/mL of benzyl benzoate and 1001.01 mg/mL of itraconazole were the optimum formulation. Observed responses were in close agreement with the predicted values of the optimized formulation, thereby demonstrating the feasibility of the optimization procedure in developing nanoparticle formulations. korn University, Bangkok, Thailand, for his invaluable help.
